At 3-D Matrix, we own an unique technology: the self-assembling peptides. We use it as a platform for various applications: in surgery as hemostatic agent, in tissue regeneration and as a drug delivery system. On the market since 2015 in Europe, we have acquired a specific know-how on manufacturing and long-proven the safety of this technology on patients.Our R&D pipeline: wound healing in GI and skin, Inflammatory Bowel Disease, hemostasis in neurosurgery, bone regeneration, drug delivery system.Management of a team of 16 people accross 3 departments: R&D, Regulatory and Quality Affairs, Operation and Supply.- MDR certification of our class III medical device- Set-up a new manufacturing line at subcontractor for double sourcing and scaling-up- Improvement of the process organization of the supply chain and sales order

Create and lead the European R&D department of 5 persons accross product develoment, clinical affairs and external collaboration. - Set-up of Design Control process- Set-up of fist-in-human clinical trial in neurosurgery- Major improvement of production yield- Research & development of wound healing applications- Manufacturing: change of sterilization and improvement of yield

Manage scientific collaborations with research lab, surgeons, biotech companies to develop new applications of 3-D Matrix peptides.Definition of the company strategy of external collaboration:- Management of KOL relationship - Spray development for hydrogel- Proof of concept in cartilage regeneration- Mucosal lifting solution for gastrointestinal resection- IP 4 patent application

Set-up collaborations with academic labs and surgeons for the development of new products in tissue regeneration and drug delivery: - Pre-clinical studies on pigs demonstrating the role of RADA16 on preventing esophageal stenosis- Hydrogel nanoparticles delivery of drug in inflammatory bowell disease- Coordination of post-market clinical trials with a CRO

Studying the role of the microbiome on the progression of Barrett’s esophagus and adenocarcinoma.

Studying the role of bile acids in the development of Barrett's esophagus and adenocarcinoma. Outcome: 4 publications.

Studying apoptosis resistance mechanism in relation with hormonal status in prostate (collaborations with AstraZeneca and clinicians).Outcome: 2 publications.